The overexpression of P-glycoprotein, encoded by the ATP Binding Cassette B1 (ABCB1) gene, contributes to multidrug resistance (MDR) and is considered one of the major obstacles to successful cancer chemotherapy. The authors previously developed a T-lineage acute lymphoblastic leukemia (T-ALL) cell line that overexpresses ABCB1 and exhibits MDR to daunorubicin (DNR), prednisolone, and vincristine. Using this cell line and the fluorescent probe JC-1, they developed a flow cytometrybased, high-throughput screening (HTS) assay that quantifies ABCB1 efflux. They screened a library of 880 off-patent drugs for their ability to inhibit ABCB1 efflux and then measured the ability of 11 lead compounds to reverse in vitro DNR-mediated drug resistance and the toxic doses for each agent. Seven of the 11 drugs were able to reverse drug resistance at a concentration significantly below its toxic dose. Of the remaining 7, only 1 compound, mometasone furoate, has not been previously described as an ABCB1 antagonist to DNR-mediated drug resistance. On the basis of its high ABC modulator activity and relatively large in vitro therapeutic window, this drug warrants further investigation. In addition, the approach used in this study is useful for identifying off-patent drugs that may be repurposed for novel clinical indications. (Journal of Biomolecular Screening 2008:185-193) 
INTRODUCTION
M ULTIDRUG RESISTANCE (MDR) IS A PROCESS that occurs when cancer cells become resistant to an array of chemotherapeutic agents. 1 The phenomenon of MDR is largely mediated by a class of 170-kD proteins that have 12 transmembrane domains and 2 adenosine triphosphate (ATP) binding cassette (ABC) sites. 2 Although more than 48 members of the ABC transporter superfamily have been identified, relatively few, such as ABCB1, ABCC1, and ABCG2, appear to have the greatest clinical impact on therapy resistance. 3 Of clinical importance, many intrinsically chemotherapy-resistant malignancies overexpress ABCB1 at the time of diagnosis. 1 Moreover, in patients with hematological malignancies, including T-lineage acute lymphoblastic leukemia (T-ALL), ABCB1 is often upregulated at the time of recurrence. 4, 5 The increased expression of ABCB1 in human cancer has important consequences for an individual's susceptibility to certain drug-induced side effects and treatment efficacy, and as a result, chemosensitizing agents have been sought to block the efflux potential of ABCB1. 1 The first ABCB1 efflux-blocking agent discovered was verapamil, a drug that belongs to a family of calcium ion influx inhibitors. Following this discovery, numerous other agents were found to block the ABCB1 drug transporter, including cyclosporine A (CSA), 6 a cyophilin-binding immunosuppressive agent. In phase I/II clinical trials, the CSA-induced complications of vomiting and confusion were generally manageable. However, more serious complications of hypertension and renal insufficiency limited the use of this drug in cancer patients 6 and called for the identification of ABCB1 transport inhibitors having less toxicity.
High-throughput screening (HTS) allows the testing of numerous cellular targets against a wide variety of potentially valuable compounds. To address the need to identify target compounds that block ABCB1-mediated drug transport, we employed HyperCyt 7 to screen a library of more than 880 off-patent drugs for potential use as chemosensitizing agents. We developed a chemoresistant T-ALL cell line that could be tested for ABCB1-reversal agents using J-aggregate-forming lipophilic cation 5,5,′6,6′-tetrachloro-1,1, ′3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1), 8, 9 a cationic dye that exhibits differential fluorescence based on its intracellular concentrations. Our initial screen identified 19 target compounds, and on the basis of a published record of safe use in humans, we investigated 11 compounds for further analysis. On the basis of an unfavorable in vitro toxicity profile, we excluded 4 drugs, leaving 7 compounds for further analysis (see Fig. 1 ). These 7 drugs have diverse structural and functional classifications and include cation channel-blocking agents, an angiotensin-converting enzyme (ACE) inhibitor, an imidazole, and an immunosuppressant. Through HTS for ABCB1-reversal agents, we also identified mometasone furoate as a drug that merits further exploration.
MATERIALS AND METHODS

Reagents, monoclonal antibodies, and cells
Daunorubicin (DNR), prednisolone (PRED), and L-asparaginase (L-asp) were purchased from Sigma-Aldrich (St. Louis, MO). Vincristine (VCR) was obtained from Faulding Pharmaceutical Company (Paramus, NJ). Phycoerythrin-conjugated (PE) mAbs against ABCB1 (USBiological, Swampscott, MA) and a PEconjugated IgG 2a isotype control (Becton Dickinson, San Jose, CA) were used in accordance with the manufacturer's recommendations. Jurkat cells were purchased from American Tissue Culture Corporation (Manassas, VA). As previously described, 10 cells were grown in RPMI 1640 medium (Gibco BRL, Grand Island, NY) with 100 units/mL penicillin-streptomycin (Gibco), 0.5 μL/L ciprofloxacin (Bayer Pharmaceuticals, Berkeley, CA), and 10% heat-inactivated fetal bovine serum (FBS). Cells were incubated at 37 °C in a humidified atmosphere of air/5% CO 2 .
Microarray preprocessing and analysis
Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Valenica, CA). RNA processing and hybridization to the Human Genome U133 Plus 2.0 oligonucleotide microarray (Affymetrix, Santa Clara, CA) were performed according to the manufacturer's protocol. Signal intensity was scaled to 500 and collected by Affymetrix GeneChip Operating Software (GCOS). Probe set intensities were normalized with the Robust Multi-Array Average (RMA) method 11 in GeneSpring 7.1 (Agilent Technologies, Palo Alto, CA). Fold-change comparisons between parental and resistant cell lines were made using GeneSpring 7.1 (Agilent).
Flow cytometric analysis of ABCB1 cell surface expression
Daunorubicin-resistant and wild-type Jurkat cells were centrifuged twice at 800 rpm (4 °C) for 3 min and resuspended in 1× phosphate-buffered saline (PBS). The cells were then incubated on ice under dark conditions for 30 min with either the PE-conjugated ABCB1 or the IgG 2a isotype control. After 2 additional rounds of centrifugation, the cells were analyzed for surface protein expression using a FACscan flow cytometer (Becton Dickinson).
JC-1 assay and flow cytometry
A recently developed flow cytometric assay evaluated the P-gp function by measuring the accumulation of JC-1 in the absence or the presence of a P-gp inhibitor. 9 Due to the stacking in a liquid crystal form, the fluorescence emission wavelength of this probe depends on its concentration. When the JC-1 monomers are excited at 488 nm, the emission spectrum reaches its maximum at 537 nm (green fluorescence). Beyond a critical concentration, JC-1 aggregates are formed and, in addition to green fluorescence, display a red fluorescence at 597 nm. Although sensitive cells display both green and red fluorescence, resistant cells display only green fluorescence. At least 10,000 events were counted (FACscan) and analyzed with IDLeQuery software. 12
Prestwick Chemical Library
The Prestwick Chemical Library is a collection of 880 offpatent small organic molecules, of which approximately 85% of the compounds have been marketed as drugs or biologically active agents. Prestwick Chemical Library compounds were provided as DMSO stock solutions and were diluted 1:50 in assay dilution buffer (110 mM NaCl, 30 mM HEPES, 10 mM KCl, 1 mM MgCl 2 , 10 mM glucose, and 0.1% bovine serum albumin) to attain DMSO concentrations of 2% prior to addition to wells. 12 To maintain enhanced cell viability, we adjusted the final DMSO concentration to 1%.
Flow cytometric detection of ABCB1 reversal (HyperCyt assay)
The quantification of ligand binding, surface antigen expression, and characterization of cellular immunophenotypic features has been reported for the HyperCyt assay. 7 The HTS response data were measured in the FL1 green fluorescence emission channel (530-540 nm), and the FL3 red fluorescence emission channel (> 650 nm) was used for detection of Cytoplex L9 or L10 beads (Duke Scientific, Palo Alto, CA). The beads were used as an internal control to facilitate the proper registration of flow cytometry data with source wells. Jurkat cells grown in the presence of 20 nM DNR were centrifuged and resuspended in 1× JC-1 buffer. Then, 100 μL of this cell suspension was added to a 96-well PCR plate (GeneMate, ISC BioExpress, Kaysville, UT) containing 80 different Prestwick compounds at a final concentration of 5 μM. The first column of 8 wells contained no compounds (negative control) and included Cytoplex L9 or L10 beads to delineate the beginning of a row, and the last column of 8 wells contained 10 μM cyclosporine A (positive control). Secondary screening of "hits" was performed in 384-well format by the same protocol except serial dilutions of the compound of interest replaced the test compounds. From these dose-response data, an EC 50 was determined using Prism (GraphPad Software, San Diego, CA).
Determination of Chem reversal50 and TD 50 concentrations
To quantify the effects of ABCB1-reversal agents in conferring sensitivity in DNR-resistant cells, we determined the ABCB1-reversal agent drug concentrations that resulted in a 50% decrease of cell viability in 100,000 Jurkat cells/mL maintained in a fixed concentration of 100 nM DNR (Chem reversal50 ). To enable this analysis, we added a 3-log range of each "hit" compound in 2-mL aliquots to a 6-well plate, and over a range of 7 days, we measured total cell number and viability using a hemacytometer and Trypan blue staining. Fresh media containing 100 nM DNR were added over the course of the experiment to maintain the cell concentration ≥100,000 cells/mL. Using a similar approach, we measured the direct toxic effects of the ABCB1-reversal agents that resulted in cell death in DNRresistant Jurkat cells maintained in media alone (Toxic Dose 50 ; hereafter, TD 50 ). Results were compared with the survival of parental cells in the presence of DNR (the positive control resulted in 100% cell death) as well as the survival of drugresistant cells in the presence of chemotherapeutic drug (the negative control yielded 100% cell viability). The differences (if any) between the Chem reversal50 and TD 50 gave an approximation of an in vitro "therapeutic index" for each compound.
Statistical analysis
To quantify intracellular variations in JC-1 fluorescence, we analyzed time-resolved HTS data using IDLeQuery; this program detects data clusters and analyzes each to determine the Z scores for fluorescence. To calculate Z scores for each HTS data set, the following equation was employed:
. In this equation, NC SD describes the standard deviation of the mean fluorescence intensity (MFI) of cells in negative control wells, PC SD describes the standard deviation of the MFI of cells in the positive control wells, and NC AVG and PC AVG describe the negative and positive average MFIs of cells in control wells, respectively. Because each sample consists of 2 μL taken from a 15-μL volume in each well, we routinely sampled and analyzed each plate twice and averaged the results.
Ligand competition curves were fit by nonlinear least squares regression using a 1-site competition model with Prism software (GraphPad Software) to determine the concentration of added competitor that inhibited fluorescent ligand binding by 50% (IC 50 ). We used Spearman's rank correlation coefficient (Rs) to study the correlation between different parameters. After classifying the results in a frequency table, a chi-square (χ 2 ) test was performed to study the relationship between the different categories.
RESULTS
Development of an ABCB1-upregulated T-ALL cell line
ABCB1 acts as a molecular pump that is capable of lowering intracellular concentrations of substrate xenobiotics, such as DNR, VCR, PRED, and a number of other chemotherapeutic agents. To investigate whether JC-1 might be used to quantify the effectiveness of ABCB1 efflux inhibitors, we first developed a T-ALL cell line with acquired resistance to DNR, a well-known ABCB1 transport substrate. 10 To confirm that DNR-induced multidrug resistance was conferred by inducible upregulation of the ABCB1 gene, we measured relative changes in ABCB1 mRNA expression between the Jurkat wild-type and DNR-resistant cell lines. We observed that ABCB1 mRNA was selectively upregulated approximately 600-fold in the resistant cell line (see Fig.  2A ). When comparing fold upregulation for other ABC transporters, to specifically include ABCC1 (multiple resistant protein, MRP) and ABCG2 (breast cancer-related protein, BCRP), we also found that mRNA levels remained unchanged (less than 1.5fold difference) between the resistant and wild-type Jurkat cell lines. To determine whether upregulation of ABCB1 mRNA resulted in increased surface expression of the ABCB1 protein, we used flow cytometry to test for ABCB1 protein expression in the Jurkat cells lines. We found that in comparison to chemosensitive cells (see Fig. 2B1, B2) , ABCB1 expression was upregulated by more than 100-fold on resistant cells. We next tested Jurkat DNR-resistant cells for acquired resistance to VCR, PRED, and L-asp, drugs that are commonly used to induce remission from T-ALL. 13 We found that Jurkat cells having acquired resistance to DNR also showed an approximately 70-fold increased resistance to VCR (IC 50 0.04 vs. 2.5 μM), a 3-fold increased resistance to PRED (IC 50 0.15 vs. 0.5 μM), but no increased resistance to L-asp (see Fig. 2C ). These data show that the DNRresistant Jurkat cell line demonstrates resistance to chemotherapeutic agents having a diverse array of structure and class distinctions. 14
Adaptation of the HyperCyt assay to identify an ABCB1-reversal "signature"
Having established that chemoresistant Jurkat cells express upregulated ABCB1 in the context of cytotoxic pressure, we next assessed whether CSA, a potent drug transport efflux inhibitor, might alter intracellular JC-1 concentrations in a flow-cytometric quantification. In comparison to unblocked chemoresistant cells, CSA inhibited the efflux of JC-1 from DNR-resistant Jurkat cells (see Fig. 3A, B) . Based on the findings of Legrand et al. 8 that JC-1 may be used to measure ABCB1 transport, we adapted the HyperCyt system to distinguish "chemical hits" in Jurkat cells showing a differential in intracellular JC-1 concentrations (see Fig. 3C ). We found that CSA and other ABCB1 drug efflux inhibitors could be identified by shifts in intracellular JC-1 concentrations and consequent fluorescence levels. This approach also allowed for the rapid screen of many compounds, thus avoiding the necessity of maintaining cells in culture for long-term periods, and likely also contributed to the high reliability of the assay. The Z′ statistics for the plate measurements (analyzed in duplicate) were 0.57 ± 0.25 (mean ± SD) for FL2 and 0.78 ± 0.13 for FL1, indicating a high level of reproducibility. Based on the concentration of the ABCB1-reversal agent, shifts in intracellular JC-1 fluorescence show a continuum of effect, allowing the exclusion of compounds having low-level signals. 
Identification of Prestwick compounds that block ABCB1-mediated JC-1 efflux
From 880 potential targets within the Prestwick Chemical Library, we identified 19 compounds (2%) as inhibiting ABCB1mediated drug efflux (see Fig. 4 ). Because we wished to identify agents that might enhance chemotherapeutics, we filtered from our analysis compounds that could not be taken internally, had unproven benefit, or had been reported to have unacceptable toxicities in humans. Using these criteria, we excluded 8 additional drugs (antimycin, thiocolchicoside, methiothenin maleate, fusidic acid, rotenone, ciclopirox ethanolamine, syrosingopine, and avermectin) from our initial list of 19 compounds, leaving 11 candidate compounds available for further investigation as chemosensitizing agents.
We next performed IC 50 analyses for each of 11 drugs to determine the relative drug efflux activity over the concentration range 0.1 nM to 1 μM. Of the 11 compounds identified for IC 50 analyses, 4 drugs are cation channel blockers, including the calcium channel blockers bepridil, lidoflazine, and nicardipine, and the sodium channel blocker, propafenone (see Fig. 4A ). For the calcium channel blockers, the IC 50 s were 0.76 ± 0.18 μM for nicardipine, 5.4 ± 0.55 μM for lidoflazine, and 7.4 ± 0.95 μM for bepridil. Propafenone had the highest IC 50 , which was measured to be 19.3 ± 2.1 μM. The screen identified 3 drugs having physiologic effects at intranuclear sites of activity, including 1 topoisomerase inhibitor, ellipticine, and 2 steroids, mometasone furoate and hexestrol (see IC 50 s ranging from 0.74 ± 0.13 to 8.3 ± 3.2 μM, respectively. The remaining 4 drugs in the screen belong to drug classes having diverse functions and structures (see Fig. 4C ). These ABCB1-reversal agents (and their respective IC 50 concentrations) include rescinnamin (1.53 ± 0.5 μM), an angiotensinconverting enzyme inhibitor; GBR 12909 (4.6 ± 0.28 μM), an inhibitor of dopamine uptake; ketaconazole (2.18 ± 0.45 μM), an antifungal; and cyclosporine A (0.31 ± 0.087 μM), a potent immunosuppressant and inhibitor of DNA binding activity. 15 Altogether, these drugs showed a 62-fold range in IC 50 concentrations in the DNR-resistant Jurkat cell line. With the exception of nicardipine, the cation channel-blocking agents had higher IC 50 s then most other agents. Conversely, drugs with intranuclear sites of activity had lower IC 50 concentrations, suggesting that the subcellular site of activity might influence each drug's anticipated efficacy and toxicity profile.
Secondary screen for cellular chemosensitization and toxicity
To verify whether the 11 compounds may have cellular effects that potentiate the effects of DNR, we performed 2 functional assays (see Fig. 5 ). In the first, we tested each compound's potential to sensitize the DNR-resistant Jurkat cells to the cytotoxic effects of DNR (Chem reversal50 ), and in the second, we assessed each compound's direct in vitro toxicity (TD 50 ). In the Chem reversal50 assay, Jurkat viability was assessed against a 5-log range of efflux inhibitor compounds in a fixed concentration of DNR, and for each of the 11 drugs, we observed dose-dependent decreases in cell viability. Within the cation channel-blocking class of compounds, we again observed a range of drug concentrations that could reverse DNR-resistant Jurkat cells line to chemosensitivity. For the calcium channel-blocking agents, the Chem reversal50 s were 3.3 ± 2.3, 3.1 ± 1.7, and 2.6 ± 1.1 μM, respectively, for bepridil, lidoflazine, and nicardipine, and for the sodium channel-blocking agent propafenone, the Chem reversal50 was 4.9 ± 1.3 μM. For the steroid derivatives mometasone and hexestrol, the Chem reversal50 s were measured to be 1.4 ± 0.28 and 12.8 ± 3.3 μM, respectively; the topoisomerase inhibitor ellipiticine had a Chem reversal50 of 1.8 ± 0.92 μM. In the remaining drug classes, the following respective Chem reversal50 s were identified: rescinnamine, 1.0 ± 0.5; GBR 12909, 2.1 ± 0.01; ketoconazole, 3.7 ± 0.99; and cyclosporine A, 0.63 ± 0.01 μM. Overall, the Chem reversal50 s for the 11 lead compounds ranged 20-fold, from cyclosporine A having the lowest Chem reversal50 value to hexestrol having the highest for the identified ABCB1-reversal agents.
Because ABCB1-reversal agents can have significant toxicities, we tested a 5-log range of drug concentrations for each hit compound to determine the TD 50 . Four drugs with indistinguishable Chem reversal50 and TD 50 curves were eliminated from consideration. In addition, drugs having a TD 50 below its reversal effect or achievable serum concentration would be likely to have a toxicity profile unsuitable for ABCB1 reversal in human use. For the cation channel-blocking agents, the TD 50 s were 24.54 ± 27.2, 9.7 ± 7.6, and 19.4 ± 5.0 μM for bepridil, lidoflazine, and nicardipine and 27.5 ± 5.0 μM for propafenone, respectively. For the steroid derivative hexestrol and mometasone, the TD 50 s were 10.6 ± 6.4 and 24.8 ± 8.0 μM, respectively, and for ellipticine, the TD 50 was 2.7 ± 1.56 μM. Among the remaining compounds, the TD 50 s were 10.00 ± 6.4 μM for rescinnamine, 5.2 ± 0.14 μM for GBR 12909, 37.9 ± 2.1 μM for ketoconazole, and 3.4 ± 2.34 μM for cyclosporine A. Overall, an 11-fold range of TD 50 s was observed in this set of compounds, the lowest observed in cyclosporine A and the highest measured in ketoconazole.
Comparative elimination of drugs having an unfavorable in vitro therapeutic index
In this comparative analysis, our goal was to exclude from further consideration compounds having similar or narrowly differing Chem reversal50 and TD 50 concentrations. As shown in Figure 5 , 4 drugs (lidoflazine, hexestrol, ellipticine, and GBR 12909) had essentially no differences between their TD 50 and Chem reversal50 concentrations. Thus, we could not distinguish whether toxicity or efficacy was promoting our inhibitory chemoreversal effects. Accordingly, these 4 agents were eliminated from further consideration, leaving 7 for further investigation (see Table 1 ).
In comparison to the previously described chemosensitizing agents that were identified in this screen, the Chem reversal50 curves for rescinnamine and mometasone furoate were most similar to those generated for ketoconazole and cyclosporine A. For these compounds, at least a 10-fold difference in drug concentration separated reversal effect from toxic effect. Among the cation channel-blocking drugs, nicardipine and propafenone have relatively narrow reversal and toxicity profiles, each being less than 10-fold, suggesting a more restrictive therapeutic index. Although correlations between IC 50 , Chem reversal50 , and TD 50 s may help to definitively exclude specific compounds from further analysis, these tests do not replace the need to perform additional studies, to include controlled clinical trials to reliably test drug combinations for safety and efficacy.
DISCUSSION
To improve outcome for cancer patients, there is a critical need to identify new targets for pharmaceutical intervention. The ability of ABCB1 inhibitors to compete with cytotoxic drugs for outward transport has been demonstrated for numerous compounds, which have been collectively termed MDR modulators, efflux inhibitors, or chemosensitizing agents. Using a JC-1-adapted, HyperCyt HTS, we evaluated 880 off-patent compounds in the Prestwick Chemical Library for drugs that inhibit ABCB1-mediated efflux. We initially identified 19 compounds having potential as chemosensitizing agents. After excluding 7 drugs that had no record for safe internal use in humans, and through additional preclinical testing, 4 additional candidates appearing to have unfavorable in vitro therapeutic indices were also removed from consideration, allowing us to further constrain our list of lead candidates to 7 compounds. Because ketoconazole, 16 bepridil, 17 nicardipine, 18 and cyclosporine A 6, 19 have been used as ABCB1-reversal agents in the clinical setting for cancer control, we further constrained our list of lead compounds to 3 agents. Interestingly, of the remaining 3 compounds, only mometasone furoate appears to be a novel ABCB1-reversal agent to DNR-mediated drug resistance. The favorable in vitro physiologic profile for this drug merits further investigation for its role as an ABCB1-reversal agent. In addition, our approach indicates that HTS of the Prestwick Chemical Library might be a fruitful approach to identifying lead candidates for novel clinical indications.
High-Throughput Screening Identifies ABCB1-Reversal Agents
Chemical libraries that are composed of established drugs can be used to screen compounds for new uses, purposes, and indications. 20 Using a novel approach to HTS, we modified the JC-1 efflux assay 8, 9 for implementation in HyperCyt 7 and, within the Prestwick Chemical Library, measured ABCB1-mediated efflux. Our high frequency of "hits," 2.15% of the library (19 of 880 compounds), is much higher than expected from HTS of random chemical structures. Our experience screening the National Institutes of Health small-molecule repository has typically found less than 1 active "hit" per 1000 compounds (Sklar and Edwards, unpublished observations). These observations appear to be similar to the experiences of others, 21, 22 indicating that biologically active chemicals (drugs) have a high tendency to interact with multiple molecular targets. This concept has been previously described, 22 but currently, we do not have a complete understanding of the chemical space that allows this phenomenon to be explained.
Traditional ABCB1 substrates include anthracyclines (DNR), vinca alkaloids (VCR), taxanes, epidopodophyllotoxins, and imatinib. 23 ABCB1 inhibitors, including first-through fourthgeneration compounds, have a medium to low molecular weight, are lipophilic, have 2 planar aromatic rings, and enter cells by passive diffusion. 24 Mometasone furoate is not an exception. Although these first-through fourth-generation compounds have been shown to have ABCB1 inhibitory effects in vitro, their results in clinical trials have been mixed. [25] [26] [27] These mixed results have been attributed to the compounds having low bioavailability, unexpected secondary physiological effects, and unanticipated drug-drug interactions. Screening libraries of known drugs might circumvent some of these pitfalls, as most lead compounds will have established drug dosing specifications and well-established toxicities when used to treat other diseases. Our approach may also expedite the introduction of lead compounds into clinical trials and avoid the labor-intensive traditional process of optimizing a lead compound over several structural generations.
Mometasone furoate is a potent corticosteroid that clearly inhibits ABCB1 efflux. Interestingly, corticosteroids have tumoricidal effects in leukemias, 13 leading to the possibility that, in selected cases, their activity may concurrently enhance the effects of other ABCB1 chemotherapy substrates while also providing direct antitumor effects. Although mometasone remains to be fully investigated for its clinical potential in cancer control, our observations indicate that this drug has a high ABC modulator activity and a relatively large in vitro therapeutic window, and this warrants further investigation.
